Rate My Professor Imran Ahmad

Professor Imran Ahmad is Professor of Urological Oncology at the CRUK Beatson Institute and the School of Cancer Sciences, University of Glasgow. He is an Honorary Consultant Urological Surgeon at Queen Elizabeth University Hospital, Glasgow, specializing in robotic surgery for advanced prostate and bladder cancer. He established the Robotic Pelvic Cancer Service in the West of Scotland as a partnership between NHS Greater Glasgow & Clyde and the University of Glasgow, trained its members, and has delivered several practice-changing clinical surgical trials over the last five years. He chairs the Scientific and Education Committee at The Urology Foundation and focuses on improving functional outcomes such as early continence recovery, erectile function, and quality of life while maintaining oncological control and addressing health inequalities in Glasgow.

Ahmad's research centers on mechanisms of treatment-resistance in advanced prostate cancer, employing state-of-the-art in vivo models and patient samples to identify drivers of progression, novel biomarkers, and drug targets. His laboratory investigates the interplay between metabolism, the immune system, and disease progression. He earned his PhD from the University of Glasgow, winning the 2013 Thomas and Margaret Smellie Prize for the best PhD thesis by a medical graduate and the Hunterian Professorship from the Royal College of Surgeons of England. Key awards include the 2022 EAU Best Paper on Fundamental Research, 2017 EAU Best Paper on Fundamental Research, 2018 American Urological Association and BAUS Visiting Scholar Programme, 2017 Chairman’s Award at NHS GG&C, and 2014 ARTP Award. Prominent publications feature 'Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer' (PNAS, 2016), 'HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer' (PNAS, 2011), 'Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos' (British Journal of Cancer, 2025), and 'Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the TRoMbone trial' (BJU International, 2022). His work profoundly impacts urological oncology through surgical advancements and fundamental research insights.